Cochrane · systematic review · CD010685
Retinoic acid postconsolidation therapy for high‐risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation
Peinemann, F, van Dalen, EC, Enk, H, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
2
No studies
5
Included studies
NR
No studies 5 · 71.4%Ungraded 0 · 0%Very low 0 · 0%Low 2 · 28.6%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsRetinoic acid postconsolidation therapy compared to no further treatment for high‐risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation
Population: high‐risk neuroblastoma patients treated with autologous HSCT
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival (reported as mortality) Retinoic acid postconsolidation therapy vs no further treatment | HR 0.87 [0.46, 1.63] | 1 study · 98 participants | Low Downgraded: risk of bias, imprecision |
Treatment‐related mortality ‐ not reported Retinoic acid postconsolidation therapy vs no further treatment | no estimate extracted | NR | No studies |
Progression‐free survival ‐ not reported Retinoic acid postconsolidation therapy vs no further treatment | no estimate extracted | NR | No studies |
Event‐free survival (reported as relapse, disease progression, death from any cause, or second neoplasm) Retinoic acid postconsolidation therapy vs no further treatment | HR 0.86 [0.5, 1.49] | 1 study · 98 participants | Low Downgraded: risk of bias, imprecision |
Early toxicity ‐ not reported Retinoic acid postconsolidation therapy vs no further treatment | no estimate extracted | NR | No studies |
Late toxicity including secondary malignancies ‐ not reported Retinoic acid postconsolidation therapy vs no further treatment | no estimate extracted | NR | No studies |
Health‐related quality of life ‐ not reported Retinoic acid postconsolidation therapy vs no further treatment | no estimate extracted | NR | No studies |